✦ LIBER ✦

Enzyme-replacement therapy in cultured tay-sachs disease brain cells

✍ Scribed by L. Schneck; S. Brooks; L. Hoffman; M. Adachi

Publisher: Springer
Year: 1982
Tongue: English
Weight: 173 KB
Volume: 5
Category: Article
ISSN: 0141-8955
DOI: 10.1007/bf01799823

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tay-Sachs disease and normal cerebellar

Tay-Sachs disease and normal cerebellar cells in culture: Elevated levels of lysosomal enzymes in Tay-Sachs disease cells

✍ Dr. Linda M. Hoffman; Steven E. Brooks; Larry Schneck 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 342 KB

## Abstract Tay‐Sachs disease and normal fetal cerebellar cells were maintained in culture for up to four weeks. Elevated levels of the lysosomal enzymes hexosaminidase B, β‐galactosidase, and acid phosphatase were observed in the Tay‐Sachs cells in long term cultures although elevated lysosomal en

Tay-sachs disease brain cells in culture

Tay-sachs disease brain cells in culture: Mobilization of stored GM2 after concanavalin A-mediated uptake of hexosaminidase A

✍ Dr. Linda M. Hoffman; Steven E. Brooks; Daniel Amsterdam; John Oropello; Larry S 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 324 KB 👁 1 views

## Abstract A human Tay‐Sachs disease (TSD) fetal‐brain‐cell line is a useful model for the disease since the cells lack hexosaminidase A and accumulate the ganglioside, G~M2~. This brain‐cell line was used to assess the effect of hexosaminidase A treatment on G~M2~ storage material. Entry of place

Long-term intracellular retention of hex

Long-term intracellular retention of hexosaminidase A by Tay-Sachs disease brain and lung cells in vitro

✍ Steven E. Brooks; Linda M. Hoffman; Daniel Amsterdam; Masazumi Adachi; Larry Sch 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 493 KB 👁 1 views

## Abstract Enzyme‐replacement treatment for metabolic storage disorders has been widely studied using model cell culture systems. This study determines the long‐term fate of human hexosaminidase A supplied to Tay‐Sachs disease brain and lung cells. Hex A retention studies showed that the incorpora

Enzyme replacement therapy induces T-cel

Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease

✍ Miklos Banati; Zsolt Hosszu; Anita Trauninger; Laszlo Szereday; Zsolt Illes 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 330 KB

## Abstract ## Introduction: Enzyme replacement therapy (ERT) in ultra‐orphan Pompe disease generates anti‐rhGAA antibodies, which may interfere with efficacy. ## Methods: rhGAA‐specific T‐cell responses were examined at different time‐points in 6 Hungarian patients treated with rhGAA and compar

Abnormal expression and processing of ur

Abnormal expression and processing of uromodulin in Fabry disease reflects tubular cell storage alteration and is reversible by enzyme replacement therapy

✍ P. Vylet’al; H. Hůlková; M. Živná; L. Berná; P. Novák; M. Elleder; S. Kmoch 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 853 KB

Partial phenotypic correction and immune

Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of α-glucosidase in Pompe disease

✍ Gaëlle Douillard-Guilloux; Emmanuel Richard; Lionel Batista; Catherine Caillaud 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 472 KB 👁 1 views

## Abstract ## Background Glycogen storage disease type II (GSDII) or Pompe disease is an inherited disease of glycogen metabolism caused by a lack of functional lysosomal acid α‐glucosidase (GAA). Affected individuals store glycogen in lysosomes resulting in fatal hypertrophic cardiomyopathy and